Company intelligence / Profile preview

Cellulac

London, England, United Kingdom

Ownership: Private
Development stage: Other

Overview

Cellulac has demonstrated commercial scale production of optically pure D(-) lactic acid from deproteinized whey for bioplastic applications and produces Omega-3 oils from microalgae at scale, supplying both food and industrial sectors. Their technologies are approved for human food grade products and are in commercial use in partnership with global companies.[3][1]

Industry: Non-Drug Biotech

Partnerships

Pharmafilter (long-term bioplastics supply agreement for hospitals in Europe)[4]Integumen (commercial technology agreement, 9.35% equity stake)[4]

Beyond the preview

Go deeper on Cellulac.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cellulac.

Explore the full profile